Editorial & Columns FY25 Review: Operational Efficiency of Pharmaceutical Companies in India July 31, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Environment, Health and Safety (EHS) Practices: Concern & Compliance in Indian Pharmaceutical Industry July 23, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Pharma Companies Gaining Foothold in Consumer Healthcare Space July 16, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Open Innovation Practices of Pharma MNCs July 8, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Torrent Pharma: New Owner of J B Chemicals and Pharmaceuticals July 3, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Licensing Route: Cues from Global Pharma MNCs for Indian Pharma Companies June 26, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Talent and Trade: Indian Pharma Industry bonds with Israel and Iran June 19, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Revenue, EBITDA and Market Capitalisation: Linkage in Valuation of Pharma Companies in India June 11, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Filling a Whitespace: Merger of Dabur India and Sesa Care June 4, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY25 Review: Profitability of Leading Pharma Companies in India May 28, 2025 | Dr. Anil Kumar Angrish | No Comments | More